• +1-646-491-9876
    • +91-20-67278686

    Search

    Fibrosarcoma - Pipeline Review, H1 2017

    Fibrosarcoma - Pipeline Review, H1 2017

    • Report Code ID: RW0001709424
    • Category Pharmaceuticals
    • No. of Pages 57
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Fibrosarcoma - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Fibrosarcoma - Pipeline Review, H1 2017, provides an overview of the Fibrosarcoma (Oncology) pipeline landscape.

    Fibrosarcoma is a malignant tumor derived from fibrous connective tissue. Symptoms include local pain, local swelling, local warmth, dilated blood vessels pain and swelling of the bone, pathological fractures, neurological and vascular changes.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Fibrosarcoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Fibrosarcoma (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Fibrosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Fibrosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 7 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

    Fibrosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Fibrosarcoma (Oncology) .
    - The pipeline guide reviews pipeline therapeutics for Fibrosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Fibrosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Fibrosarcoma (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Fibrosarcoma (Oncology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Fibrosarcoma (Oncology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Fibrosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Fibrosarcoma - Overview
    Fibrosarcoma - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Fibrosarcoma - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Fibrosarcoma - Companies Involved in Therapeutics Development
    Advanced Proteome Therapeutics Corp
    Advenchen Laboratories LLC
    Bicycle Therapeutics Ltd
    Daiichi Sankyo Company Ltd
    Elsalys Biotech SAS
    Intezyne Technologies Inc
    Novartis AG
    Pharma Mar SA
    SOM Biotech SL
    Sumitomo Dainippon Pharma Co Ltd
    Fibrosarcoma - Drug Profiles
    AL-3818 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Antisense Oligonucleotides to Inhibit Rho-GAP for Colon Cancer and Fibrosarcoma - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    APC-103 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BT-1718 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cellular Immunotherapy for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    daunorubicin hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DSR-6434 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ELB-021 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    everolimus - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LK-3 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MI-130110 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PLX-7486 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SEN-461 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SOM-0777 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Fibrosarcoma - Dormant Projects
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Fibrosarcoma, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Fibrosarcoma - Pipeline by Advanced Proteome Therapeutics Corp, H1 2017
    Fibrosarcoma - Pipeline by Advenchen Laboratories LLC, H1 2017
    Fibrosarcoma - Pipeline by Bicycle Therapeutics Ltd, H1 2017
    Fibrosarcoma - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
    Fibrosarcoma - Pipeline by Elsalys Biotech SAS, H1 2017
    Fibrosarcoma - Pipeline by Intezyne Technologies Inc, H1 2017
    Fibrosarcoma - Pipeline by Novartis AG, H1 2017
    Fibrosarcoma - Pipeline by Pharma Mar SA, H1 2017
    Fibrosarcoma - Pipeline by SOM Biotech SL, H1 2017
    Fibrosarcoma - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
    Fibrosarcoma - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Fibrosarcoma, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Advanced Proteome Therapeutics Corp
    Advenchen Laboratories LLC
    Bicycle Therapeutics Ltd
    Daiichi Sankyo Company Ltd
    Elsalys Biotech SAS
    Intezyne Technologies Inc
    Novartis AG
    Pharma Mar SA
    SOM Biotech SL
    Sumitomo Dainippon Pharma Co Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//fibrosarcoma-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//fibrosarcoma-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//fibrosarcoma-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments